Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B ...

Luke Miels, Chief Commercial Officer, GSK, said: “IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that ...